Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 170

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Weight gain from novel antipsychotic drugs: need for action

Green, Alan I, Patel, Jayendra K, Goisman, Robert M, Allison, David B, Blackburn, George · 2000 · General Hospital Psychiatry

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0163-8343(00)00081-5

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 137

  1. Andreasen, 1999, Understanding the causes of schizophrenia, N Eng J Med, 340, 645, 10.1056/NEJM199902253400811 · DOI
  2. Ho, 1997, Dependence on public financial support early in the course of schizophrenia, Psychiatr Serv, 48, 948, 10.1176/ps.48.7.948 · DOI
  3. Cohen, 1990, Suicide and schizophrenia, Am J Psychiatry, 147, 602, 10.1176/ajp.147.5.602 · DOI · Paper page
  4. Axelsson, 1992, Factors predicting suicide in psychotic patients, Eur Arch Psychiatr Clin Neurosci, 241, 259, 10.1007/BF02195974 · DOI
  5. Bernstein, 1987, Induction of obesity by psychotropic drugs, Ann NY Acad Sci, 499, 203, 10.1111/j.1749-6632.1987.tb36212.x · DOI
  6. Allison, 1999, The distribution of body mass index among individuals with and without schizophrenia, J Clin Psychiatry, 60, 215, 10.4088/JCP.v60n0402 · DOI · Paper page
  7. Beasley CM: Safety of olanzapine. J Clin Psychiatry Monograph 1997a;15(2):19–21, 1997a
  8. Stanton, 1995, Weight gain associated with neuroleptic medication, Schizophr Bull, 21, 463, 10.1093/schbul/21.3.463 · DOI
  9. Kando, 1997, Olanzapine, Ann Pharmacother, 31, 1325, 10.1177/106002809703101110 · DOI
  10. Umbricht, 1994, Clozapine and weight gain, J Clin Psychiatry, 55, 157
  11. 1998, Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report, Obes Res, 6, 51S
  12. Pijl, 1996, Body weight change as an adverse effect of drug treatment, Drug Safety, 14, 329, 10.2165/00002018-199614050-00005 · DOI
  13. Andreasen, 1998, “Cognitive dysmetria” as an integrative theory of schizophrenia, Schizophr Bull, 24, 203, 10.1093/oxfordjournals.schbul.a033321 · DOI · Paper page
  14. Woods, 1998, Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenic mechanism, Am J Psychiatry, 155, 1661, 10.1176/ajp.155.12.1661 · DOI · Paper page
  15. Jones, 1991, The genetics of schizophrenia is the genetics of neurodevelopment, Br J Psychiatry, 158, 615, 10.1192/bjp.158.5.615 · DOI · Paper page
  16. Armstrong, 1995, The ontogeny of human gyrification, Cereb Cortex, 5, 56, 10.1093/cercor/5.1.56 · DOI · Paper page
  17. McGlashan, 1988, A selective review of recent North American long-term follow-up studies of schizophrenia, Schizophr Bull, 14, 514
  18. Eaton, 1992, Long-term course of hospitalization for schizophrenia, Schizophr Bull, 18, 217, 10.1093/schbul/18.2.217 · DOI · Paper page
  19. Kenny, 1991, Attention of higher cortical functions in schizophrenia, J Neuropsychiatr Clin Neurosci, 3, 269, 10.1176/jnp.3.3.269 · DOI
  20. Saykin, 1991, Neuropsychological function in schizophrenia, Arch Gen Psychiatry, 48, 618, 10.1001/archpsyc.1991.01810310036007 · DOI · Paper page
  21. Seidman, 1995, Experimental and clinical neuropsychological measures of prefrontal dysfunction in schizophrenia, Neuropsychology, 9, 481, 10.1037/0894-4105.9.4.481 · DOI
  22. Bellack, 1992, Cognitive rehabilitation for schizophrenia, Schizophr Bull, 18, 43, 10.1093/schbul/18.1.43 · DOI
  23. Jaeger, 1992, Remediation of neuropsychological deficits in psychiatric populations, Psychopharmacol Bull, 28, 367
  24. Regier, 1990, Comorbidity of mental disorders with alcohol and other drug abuse, JAMA, 264, 2511, 10.1001/jama.264.19.2511 · doi:10.1001/jama.264.19.2511 · Paper page
  25. Green, 1999, Substance use disorder and schizophrenia, Harv Rev Psychiatry, 6, 289
  26. Tsuang, 1978, Suicide in schizophrenics, manics, depressives, and surgical controls, Arch Gen Psychiatry, 35, 153, 10.1001/archpsyc.1978.01770260031002 · DOI · Paper page
  27. Meltzer, 1995, Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia, Am J Psychiatry, 152, 183, 10.1176/ajp.152.2.183 · DOI · Paper page
  28. Davis, 1975, Overview, Am J Psychiatry, 132, 1237, 10.1176/ajp.132.12.1237 · DOI · Paper page
  29. Marder, 1994, Risperidone in the treatment of schizophrenia, Am J Psychiatry, 151, 825, 10.1176/ajp.151.6.825 · DOI · Paper page
  30. Meltzer, 1994, Recent advances in the pharmacotherapy of schizophrenia, Acta Psychiatr Scand Suppl, 384, 95, 10.1111/j.1600-0447.1994.tb05897.x · DOI
  31. Kane J: Olanzapine in the long-term treatment of schizophrenia. Br J Psychiatry 1999;174(suppl 37):26–29 · DOI
  32. Kane, 1988, Clozapine Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic, Arch Gen Psychiatry, 45, 789, 10.1001/archpsyc.1988.01800330013001 · DOI · Paper page
  33. Jibson, 1996, A summary of research findings on the new antipsychotic drugs, Essent Psychopharmacol, 1, 27
  34. Small, 1997, Quetiapine inpatients with schizophrenia, Arch Gen Psychiatry, 54, 549, 10.1001/archpsyc.1997.01830180067009 · DOI · Paper page
  35. Bymaster, 1999, Olanzapine, Br J Psychiatry, 174, 36, 10.1192/S0007125000293653 · DOI
  36. Breier, 1994, Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia, Am J Psychiatry, 151, 20, 10.1176/ajp.151.1.20 · DOI · Paper page
  37. Green, 1995, Should clozapine be a first-line treatment for schizophrenia, Harv Rev Psychiatry, 3, 1, 10.3109/10673229509017159 · DOI
  38. Stone, 1997, Effects of clozapine on cognitive functioning in treatment-refractory schizophrenia, Schizophrenia Res, 24, 188, 10.1016/S0920-9964(97)82539-X · doi:10.1016/s0920-9964(97)82539-x
  39. Breier, 1999, Cognitive deficit in schizophrenia and its neurochemical basis, Br J Psych, 174, 16, 10.1192/S0007125000293604 · DOI
  40. Lindstrom, 1988, The effect of long-term treatment with clozapine in schizophrenia, Acta Psychiatr Scand, 77, 524, 10.1111/j.1600-0447.1988.tb05164.x · DOI · Paper page
  41. Meltzer, 1992, Dimensions of outcome with clozapine, Br J Psychiatry, 160, 46, 10.1192/S000712500029692X · DOI · Paper page
  42. Albanese, 1994, Decreased substance use in chronically psychotic patients treated with clozapine, Am J Psychiatry, 151, 780, 10.1176/ajp.151.5.780b · DOI
  43. Drake RE, Xie H, McHugo GJ, Green AI: The effects of clozapine on alcohol and drug use disorders among schizophrenic patients. Schizophr Bull, in press
  44. Gerlach, 1994, Motor and mental side effects of clozapine, J Clin Psychiatry, 55, 107
  45. Kerwin, 1994, The new atypical antipsychotics, Br J Psychiatry, 164, 141, 10.1192/bjp.164.2.141 · DOI · Paper page
  46. McGlashan, 1996, Early detection and intervention in schizophrenia research, Schizophrenia Bull, 22, 327, 10.1093/schbul/22.2.327 · DOI · Paper page
  47. Post, 1956, Body-weight changes in psychiatric illness, J Psychosom Res, 1, 219, 10.1016/0022-3999(56)90025-3 · doi:10.1016/0022-3999(56)90025-3
  48. Amdisen, 1964, Drug-produced obesity, Dan Med Bull, 11, 182
  49. Caffey, 1971, Experience with large scale interhospital co-operative research in chemotherapy, Am J Psychiatry, 117, 713, 10.1176/ajp.117.8.713 · doi:10.1176/ajp.117.8.713
  50. Doss, 1979, The effect of antipsychotic drugs on body weight, J Clin Psychiatry, 40, 528
  51. Silverstone, 1988, Prevalence of obesity in patients receiving depot antipsychotics, Br J Psychol, 153, 214, 10.1192/bjp.153.2.214 · DOI
  52. Stedman, 1993, The distribution of adipose tissue in female inpatients receiving psychotropic drugs, Br J Psychiatry, 162, 249, 10.1192/bjp.162.2.249 · DOI
  53. Centorrino, 1994, Clozapine and metabolites, J Clin Psychopharmacol, 14, 119, 10.1097/00004714-199404000-00006 · DOI
  54. Wirshing, 1998, Novel antipsychotics and new onset diabetes, Biol Psychiatry, 44, 778, 10.1016/S0006-3223(98)00100-0 · DOI · Paper page
  55. Leadbetter, 1992, Clozapine-induced weight gain, Am J Psychiatry, 149, 68, 10.1176/ajp.149.1.68 · DOI · Paper page
  56. Casey, 1996, Side effect profiles of new antipsychotic agents, J Clin Psychiatry, 57, 40
  57. Kane, 1997, What are the therapeutic needs in schizophrenia and how are they satisfied by new antipsychotics?, Int Clin Psychopharmacol, 12, S3, 10.1097/00004850-199705002-00002 · DOI
  58. Beasley, 1997, Safety of olanzapine, J Clin Psychiatry, 58, 13
  59. Bromel, 1998, Serum leptin levels increase rapidly after initiation of clozapine therapy, Mol Psychiatry, 3, 76, 10.1038/sj.mp.4000352 · DOI · Paper page
  60. Sussman, 1999, Effects of psychotropic drugs on weight, Psychiatric Ann, 29, 580, 10.3928/0048-5713-19991001-08 · doi:10.3928/0048-5713-19991001-08
  61. Lamberti, 1992, Weight gain among schizophrenic patients treated with clozapine, Am J Psychiatry, 149, 689, 10.1176/ajp.149.5.689 · doi:10.1176/ajp.149.5.689
  62. Bustillo, 1996, Differential effect of clozapine on weight, Am J Psychiatry, 153, 817, 10.1176/ajp.153.6.817 · DOI
  63. Wirshing, 1999, Novel antipsychotics, J Clin Psychiatry, 60, 358, 10.4088/JCP.v60n0602 · DOI · Paper page
  64. Kelly, 1998, Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months, J Child Adolesc Psychopharmacol, 8, 151, 10.1089/cap.1998.8.151 · DOI
  65. McDougle, 1998, A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders, Arch Gen Psych, 55, 633, 10.1001/archpsyc.55.7.633 · DOI · Paper page
  66. Young, 1986, Medication compliance in schizophrenia, Bull Am Acad Psychiatry Law, 14, 105
  67. Robinson, 1999, Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder, Arch Gen Psychiatry, 56, 241, 10.1001/archpsyc.56.3.241 · DOI · Paper page
  68. Lieberman, 1996, Atypical antipsychotic drugs as a first-line treatment of schizophrenia, J Clin Psychiatry, 57, 68
  69. Robinson, 1975, Measurement of appetite disturbances in psychiatric disorders, J Psychiatr Res, 12, 59, 10.1016/0022-3956(75)90021-7 · DOI
  70. Cookson, 1991, Side effects during long-term treatment with a depot antipsychotic medication, Clin Neuropharm, 14, S24
  71. Mukherjee, 1996, Diabetes mellitus in schizophrenic patients, Compr Psychiatry, 37, 68, 10.1016/S0010-440X(96)90054-1 · DOI · Paper page
  72. McKee, 1986, Diabetes and schizophrenia—a preliminary study, J Clin Hosp Pharm, 11, 297
  73. Tsuang, 1993, Physical diseases in schizophrenia and affective disorder, J Clin Psychiatry, 44, 42
  74. Brambilla, 1976, Glucose-insulin metabolism in chronic schizophrenia, Dis Nerv Syst, 37, 98
  75. Williamson, 1993, Descriptive epidemiology of body weight and weight change in U.S. adults, Ann Intern Med, 119, 646, 10.7326/0003-4819-119-7_Part_2-199310011-00004 · DOI · Paper page
  76. Gill, 1997, Key issues in the prevention of obesity, Br Med Bull, 53, 359, 10.1093/oxfordjournals.bmb.a011618 · DOI
  77. Lee, 1992, Change in body weight and longevity, JAMA, 268, 2045, 10.1001/jama.268.15.2045 · DOI
  78. Rimm, 1995, Body size and fat distribution as markers of coronary heart disease among young and older men, Am J Epidemiol, 141, 1117, 10.1093/oxfordjournals.aje.a117385 · DOI · Paper page
  79. Liese, 1998, Development of the multiple metabolic syndrome, Epidemiol Rev, 20, 157, 10.1093/oxfordjournals.epirev.a017978 · DOI · Paper page
  80. Maggio, 1997, The prevention and treatment of obesity. Application to type 2 diabetes, Diabetes Care, 20, 1744, 10.2337/diacare.20.11.1744 · DOI · Paper page
  81. Blackburn, 1995, Effect of degree of weight loss on health benefits, Obes Res, 3, 211S, 10.1002/j.1550-8528.1995.tb00466.x · DOI · Paper page
  82. Ferrannini, 1993, Syndrome X, Horm Res, 39, 107, 10.1159/000182795 · DOI
  83. Reaven, 1993, Role of insulin resistance in human disease (syndrome X), Annu Rev Med, 44, 121, 10.1146/annurev.me.44.020193.001005 · DOI · Paper page
  84. Mantzoros, 1995, Insulin resistance, Adv Endocrinol Metab, 6, 193
  85. Everson, 1998, Weight gain and the risk of developing insulin resistance syndrome, Diabetes Care, 21, 1637, 10.2337/diacare.21.10.1637 · DOI
  86. Eckel, 1998, American Heart Association call to action, Circulation, 97, 2099, 10.1161/01.CIR.97.21.2099 · DOI · Paper page
  87. Schultz, 1999, Impaired glucose tolerance and abnormal movements in patients with schizophrenia, Am J Psychiatry, 156, 640, 10.1176/ajp.156.4.640 · doi:10.1176/ajp.156.4.640
  88. Glenny, 1997, The treatment and prevention of obesity, Int J Obes, 21, 715, 10.1038/sj.ijo.0800495 · DOI · Paper page
  89. Kramer, 1986, Maintenance of successful weight loss over 1 year, Behaviour Therapy, 17, 295, 10.1016/S0005-7894(86)80058-2 · DOI
  90. Ditschuneit, 1999, Metabolic and weight loss effects of long-term dietary intervention in obese patients, Am J Clin Nutr, 69, 198, 10.1093/ajcn/69.2.198 · DOI · Paper page
  91. Pronk, 1994, Physical activity and long-term maintenance of weight loss, Obes Res, 2, 587, 10.1002/j.1550-8528.1994.tb00110.x · DOI · Paper page
  92. Baum, 1991, Preventing relapse in obesity through post-treatment maintenance systems, J Behavioral Med, 14, 287, 10.1007/BF00845456 · DOI
  93. Miura, 1989, The long term effectiveness of combined therapy by behavior modification and very low calorie diet, Inter J Obes, 13, 73
  94. Wadden, 1997, Lifestyle modifications in the pharmacologic treatment of obesity, Obes Res, 5, 218, 10.1002/j.1550-8528.1997.tb00296.x · DOI
  95. Rotatori, 1980, Weight loss with psychiatric residents in a behavioral self-control program, Psychological Rep, 46, 483, 10.2466/pr0.1980.46.2.483 · DOI
  96. Ferster, 1962, The control of eating, J Mathetics, 1, 87
  97. Knox, 1980, A study of weight reducing diets in psychiatric in-patients, Br J Psychia, 136, 287, 10.1192/bjp.136.3.287 · DOI
  98. Klien, 1972, Reinforcement and weight loss in schizophrenics, Psycol Rep, 30, 581, 10.2466/pr0.1972.30.2.581 · DOI
  99. Stuart, 1967, Behavioral control of overeating, Behav Res Ther, 5, 357, 10.1016/0005-7967(67)90027-7 · DOI · Paper page
  100. Menditto, 1996, Effectiveness of clozapine and a social learning program for severely disabled psychiatric inpatients, Psychiatric Services, 47, 46, 10.1176/ps.47.1.46 · doi:10.1176/ps.47.1.46
  101. Smith, 1996, Training hospitalized patients with schizophrenia in community reintegration skills, Psychiatric Services, 47, 1099, 10.1176/ps.47.10.1099 · DOI
  102. Goisman, 1998, Social skills training, atypical neuroleptics and treatment-refractory psychosis, Int Rev Psychiatry, 10, 84, 10.1080/09540269875168 · doi:10.1080/09540269875168
  103. Liberman, 1994, Optimal drug and behavior therapy for treatment-refractory schizophrenic patients, Am J Psychiatry, 151, 756, 10.1176/ajp.151.5.756 · DOI
  104. Psychiatric Rehabilitation Consultants: Social and independent living skills: symposium management module trainer’s manual. 1988
  105. Liberman, 1993, Innovations in skills training for the seriously mentally ill, Innovations Res, 2, 43
  106. Dengel, 1998, Improvements in blood pressure, glucose metabolism and lipoprotein lipids after aerobic exercise plus weight loss in obese, hypertensive middle-aged men, Metabolism, 47, 1075, 10.1016/S0026-0495(98)90281-5 · DOI
  107. DiPietro, 1998, Moderate-intensity aerobic training improves glucose tolerance in aging independent of abdominal adiposity, J Am Geriatr Soc, 46, 875, 10.1111/j.1532-5415.1998.tb02722.x · DOI
  108. Segal, 1991, Effect of exercise training on insulin sensitivity and glucose metabolism in lean, obese, and diabetic men, J Appl Physiol, 71, 2402, 10.1152/jappl.1991.71.6.2402 · DOI · Paper page
  109. Pratt, 1999, Benefits of lifestyle activity versus structured exercise, JAMA, 281, 375, 10.1001/jama.281.4.375 · DOI
  110. Sallis, 1998, Environmental and policy interventions to promote physical activity, Am J Prev Med, 15, 379, 10.1016/S0749-3797(98)00076-2 · DOI · Paper page
  111. Yanovski, 1996, National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity, JAMA, 276, 1907, 10.1001/jama.276.23.1907 · DOI
  112. Goldstein, 1992, Beneficial health effects of modest weight loss, Int J Obes, 16, 379
  113. Atkinson, 1994, Report on the NIH Workshop on Pharmacologic Treatment of Obesity, Am J Clin Nutr, 60, 153, 10.1093/ajcn/60.2.153 · DOI
  114. Weintraub, 1981, Determinants of response to anorexiants, Clin Pharmacol Ther, 30, 528, 10.1038/clpt.1981.198 · DOI
  115. Bray, 1999, Sibutramine produces dose-related weight loss, Obes Res, 7, 189, 10.1002/j.1550-8528.1999.tb00701.x · DOI · Paper page
  116. Cleare, 1996, Phentermine, psychosis, and family history, J Clin Psychopharmacol, 16, 470, 10.1097/00004714-199612000-00020 · doi:10.1097/00004714-199612000-00020
  117. Devan, 1990, Phentermine and psychosis, Br J Psychiatry, 156, 442, 10.1192/bjp.156.3.442 · doi:10.1192/bjp.156.3.442
  118. Shannon, 1974, Fenfluramine and psychosis, Br Med J, 3, 576, 10.1136/bmj.3.5930.576-b · DOI
  119. Bagri, 1998, Delerium with manic symptoms induced by diet pills, J Clin Psychiatry, 59, 83, 10.4088/JCP.v59n0207d · doi:10.4088/jcp.v59n0207d
  120. Khan, 1987, Psychotomimetic effects of anorectic drugs, Am Fam Physician, 36, 107
  121. Dietz, 1981, Amphetamine-like reactions to phenylpropanolamine, JAMA, 245, 601, 10.1001/jama.245.6.601 · DOI
  122. Schaeffer, 1980, Psychotic reaction caused by proprietary oral diet agents, Am J Psychiatry, 137, 1256, 10.1176/ajp.137.10.1256 · doi:10.1176/ajp.137.10.1256
  123. Ryan, 1995, Sibutramine, Obes Res, 3, 553S, 10.1002/j.1550-8528.1995.tb00227.x · DOI
  124. Bray, 1996, A double-blind randomized placebo-controlled trial of sibutramine, Obes Res, 263, 10.1002/j.1550-8528.1996.tb00544.x · DOI · Paper page
  125. Weintraub, 1992, Long-term weight control study, Clin Pharmacol Therapeut, 51, 642, 10.1038/clpt.1992.76 · DOI · Paper page
  126. Scheen AJ, Lefebvre PJ: Pharmacological treatment of obesity: present status. Int J Obes Relat Metab Disord 23(suppl 1):S47–S53, 1999 · DOI
  127. Apfelbaum, 1999, Long-term maintenance of weight loss after a very-low-calorie diet, Am J Med, 106, 179, 10.1016/S0002-9343(98)00411-2 · DOI · Paper page
  128. Guerciolini, 1997, Mode of action of orilistat, Int J Obes Relat Metab Disord, 21, S12
  129. Bray, 1998, Obesity, Lancet, 352, 160, 10.1016/S0140-6736(98)22029-0 · DOI
  130. Gaal, 1998, Efficacy and tolerability of orlistat in the treatment of obesity, Eur J Clin Pharmacol, 54, 125, 10.1007/s002280050433 · DOI
  131. Sjostrom, 1998, Randomised placebo-controlled trial for orlistat for weight loss and prevention of weight gain in obese patients, Lancet, 352, 167, 10.1016/S0140-6736(97)11509-4 · DOI · Paper page
  132. McNeely, 1998, Orlistat, Drugs, 56, 241, 10.2165/00003495-199856020-00007 · DOI
  133. Zhi, 1996, The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers, Pharmacology, 36, 152
  134. Melia, 1996, The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers, J Clin Pharmacol, 36, 647, 10.1002/j.1552-4604.1996.tb04230.x · DOI
  135. Ayllon, 1963, Intensive treatment of psychotic behavior by stimulus satiation and food reinforcement, Behav Res Ther, 21, 53, 10.1016/0005-7967(63)90008-1 · DOI
  136. Bernard, 1968, Rapid treatment of gross obesity by operant techniques, Psychol Rep, 23, 663, 10.2466/pr0.1968.23.2.663 · DOI
  137. Harmatz, 1968, Behavior modification of overeating in a psychiatric population, JCCP, 32, 583

Cited by

See all 170

Metadata

Authors
Green, A. I., Patel, J. K., Goisman, R. M., Allison, D. B., & Blackburn, G.
Venue
General Hospital Psychiatry
Publisher
Elsevier BV
Published
2000-07
Volume
22
Issue
4
Pages
224-235
ISSN
0163-8343 (ISSN-L)
OpenAlex
W1977544418
Cited by
170
References
12
FWCI
7.35
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Weight gain from novel antipsychotic drugs: need for action. https://app.cochat.ai/papers/10.1016/s0163-8343(00)00081-5
The paper
Green, A. I., Patel, J. K., Goisman, R. M., Allison, D. B., & Blackburn, G. (2000). Weight gain from novel antipsychotic drugs: need for action. General Hospital Psychiatry. https://doi.org/10.1016/s0163-8343(00)00081-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.